[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-295799-105":59,"doc-detail-295799-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-issue-1-january-2013","KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease - Issue 1 - January 2013","","KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease presents an evidence-based framework for defining, classifying, identifying, and predicting chronic kidney disease (CKD) and for managing progression and complications. The guideline organizes recommendations across multiple chapters, including CKD nomenclature, prognosis, assessment of kidney function, and care pathways such as referral to specialists. It also includes tables and figures supporting grading of recommendations and quality of evidence.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-issue-1-january-2013/295799/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kdigo-2012-clinical-practice-guideline-for-the-evaluation-and-management-of-chronic-kidney-disease-issue-1-january-2013/295799.png","ImageObject",300,407,{"name":92,"@type":93},"Gelato","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-18",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the KDIGO 2012 guideline cover for chronic kidney disease?","Question",{"text":113,"@type":114},"It covers evaluation, classification, identification, prediction of CKD progression, and management of progression and complications, organized across multiple chapters and supported by tables and figures.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the guideline address CKD definitions and progression?",{"text":118,"@type":114},"It includes chapters focused on CKD definition, identification, prediction of progression, and prognosis, along with nomenclature and classification approaches.",{"name":120,"@type":111,"acceptedAnswer":121},"How are recommendations supported within the guideline?",{"text":122,"@type":114},"The document includes sections for guideline development methods and grading, supported by tables detailing evidence grading and the balance of benefits and harms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},295799,1789723853,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":130,"read_time":145},19241457091524,"https://us-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of  \nChronic Kidney Disease  \nvolume 3 | issue 1 | JANuARY 2013 [http://www.kidney-international.org](http://www.kidney-international.org)  \nKDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease  \nKDIGO gratefully acknowledges the following consortium of sponsors that make our initiatives possible: Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole Food Company, Fresenius Medical Care, Genzyme, Hoffmann-LaRoche, JC Penney, Kyowa Hakko Kirin, NATCO—The Organization for Transplant Professionals, NKF-Board of Directors, Novartis, Pharmacosmos, PUMC Pharmaceutical, Robert and Jane Cizik Foundation, Shire, Takeda Pharmaceutical, Transwestern Commercial Services, Vifor Pharma, and Wyeth.  \nSponsorship Statement: KDIGO is supported by a consortium of sponsors and no funding is accepted for the development of specific guidelines.  \nVOL 3| ISSUE 1 |JANUARY (1) 2013  \nKDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease  \nv Tables and Figures  \nvii KDIGO Board Members viii Reference Keys  \nx CKD Nomenclature  \nxi Conversion Factors & HbA1c Conversion xii Abbreviations and Acronyms  \n1 Notice  \n2 Foreword  \n3 Work Group Membership  \n4 Abstract  \n5 Summary of Recommendation Statements  \n15 Introduction: The case for updating and context  \n19 Chapter 1: Definition, and classification of CKD  \n63 Chapter 2: Definition, identification, and prediction of CKD progression  \n73 Chapter 3: Management of progression and complications of CKD  \n91 Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD  \n112 Chapter 5: Referral to specialists and models of care  \n120 Methods for Guideline Development  \n128 Biographic and Disclosure Information  \n134 Acknowledgments  \n136 References  \nThis journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE) [www.publicationethics.org](www.publicationethics.org)  \n& 2013 KDIGO  \nTABLES  \n18 Table 1. KDIGO nomenclature and description for grading recommendations  \n20 Table 2. Criteria for CKD  \n20 Table 3. Criteria for definition of CKD  \n27 Table 4. Classification of CKD based on presence or absence of systemic disease and location within the kidney of pathologic-anatomic findings  \n27 Table 5. GFR categories in CKD  \n28 Table 6. Albuminuria categories in CKD  \n31 Table 7. Relationship among categories for albuminuria and proteinuria  \n32 Table 8. CGA staging of CKD: examples of nomenclature and comments  \n33 Table 9. Prognosis of CKD: Relationship of outcomes and strength of relationship to Cause (C), GFR (G), Albuminuria (A) and other measures  \n35 Table 10. Annual percentage change in GFR across diagnosis categories  \n39 Table 11. Sources of error in GFR estimating using creatinine  \n41 Table 12. Equations based on serum creatinine assays in adults that are traceable to the standard reference material  \n44 Table 13. Performance comparison of creatinine-based GFR estimating equations in North America, Europe, and Australia  \n48 Table 14. Performance comparison of creatinine-based GFR estimating equations outside of North America, Europe, and Australia  \n50 Table 15. Sources of error in GFR estimating using cystatin C  \n52 Table 16. Equations based on IDMS traceable creatinine and IFCC traceable cystatin C assays  \n54 Table 17. Performance comparison of cystatin C-based estimating equations in North American and European populations  \n55 Table 18. Strengths and limitations of GFR measurement methods and markers  \n59 Table 19. Factors affecting urinary ACR  \n64 Table 20. Decline in kidney function in various populations (longitudinal studies only)  \n65 Table 21. Decline in kidney function in CKD populations  \n67 Table 22. Studies ev","cbCaiaEqN3S9t9Kb","https://ap.wps.com/l/cbCaiaEqN3S9t9Kb","pdf",4548193,163,"English","# Notice\n# Foreword\n# Work Group Membership\n# Abstract\n# Summary of Recommendation Statements\n# Introduction: The case for updating and context\n# Chapter 1: Definition, and classification of CKD\n# Chapter 2: Definition, identification, and prediction of CKD progression\n# Chapter 3: Management of progression and complications of CKD\n# Chapter 4: Other complications of CKD\n# Chapter 5: Referral to specialists and models of care\n# Methods for Guideline Development\n# Biographic and Disclosure Information\n# Acknowledgments\n# References","[{\"question\":\"What does the KDIGO 2012 guideline cover for chronic kidney disease?\",\"answer\":\"It covers evaluation, classification, identification, prediction of CKD progression, and management of progression and complications, organized across multiple chapters and supported by tables and figures.\"},{\"question\":\"How does the guideline address CKD definitions and progression?\",\"answer\":\"It includes chapters focused on CKD definition, identification, prediction of progression, and prognosis, along with nomenclature and classification approaches.\"},{\"question\":\"How are recommendations supported within the guideline?\",\"answer\":\"The document includes sections for guideline development methods and grading, supported by tables detailing evidence grading and the balance of benefits and harms.\"}]","KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease - Issue 1 - January 2013 | PDF",411]